StockNews.com Lowers Horizon Therapeutics Public (NASDAQ:HZNP) to Buy

Horizon Therapeutics Public (NASDAQ:HZNP) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday.

A number of other equities analysts also recently commented on the stock. TheStreet downgraded shares of Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a research note on Monday, May 8th. Jefferies Financial Group lowered shares of Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research note on Friday. Eight investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $110.71.

Horizon Therapeutics Public Price Performance

HZNP stock opened at $115.30 on Tuesday. The business’s 50-day moving average is $103.85 and its two-hundred day moving average is $105.87. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.27 and a quick ratio of 4.09. The firm has a market capitalization of $26.40 billion, a P/E ratio of 61.66, a P/E/G ratio of 3.50 and a beta of 1.05. Horizon Therapeutics Public has a 1 year low of $59.16 and a 1 year high of $115.70.

Horizon Therapeutics Public (NASDAQ:HZNP) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.08. Horizon Therapeutics Public had a net margin of 12.02% and a return on equity of 20.46%. The firm had revenue of $945.00 million for the quarter, compared to analysts’ expectations of $873.52 million. During the same quarter last year, the company earned $1.07 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year. Analysts anticipate that Horizon Therapeutics Public will post 4.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Horizon Therapeutics Public

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HZNP. T. Rowe Price Investment Management Inc. acquired a new position in Horizon Therapeutics Public during the 4th quarter valued at approximately $460,920,000. Soros Fund Management LLC acquired a new position in Horizon Therapeutics Public in the 4th quarter worth approximately $325,297,000. Norges Bank acquired a new stake in Horizon Therapeutics Public during the 4th quarter worth about $249,778,000. Avoro Capital Advisors LLC raised its position in Horizon Therapeutics Public by 36.6% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,000,000 shares of the biopharmaceutical company’s stock valued at $796,600,000 after acquiring an additional 1,875,000 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its stake in shares of Horizon Therapeutics Public by 46.7% during the 1st quarter. Farallon Capital Management LLC now owns 5,419,823 shares of the biopharmaceutical company’s stock worth $591,519,000 after acquiring an additional 1,724,900 shares in the last quarter. 80.37% of the stock is owned by hedge funds and other institutional investors.

About Horizon Therapeutics Public

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.